{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:14Z","timestamp":1787027294093,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A number of studies have shown the feasibility of using adjunctive drugs in late onset psychosis (LOP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Testing hypothesis that among LOP people treated with antipsychotics and antidepressants, basing on certain clinical characteristics a subgroup of patients might be distinguished, for whom adjunctive therapy is advantageous. This subgroup might be identified by measurement of blood biochemical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>59 in-patients with LOP, treated neuroleptics and antidepressants, were included, and followed in real clinical practice. Database containing demographic, clinical data (scores by PANSS, CDSS, CGI-S, HAMD-17), prescribed therapy, adverse effects of antipsychotic and antidepressant treatment, and blood biochemical parameters (enzymatic activities of glutamate- and glutathione metabolism enzymes in platelets and erythrocytes) at baseline and after the treatment course was created.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three groups of patients (Gr1, Gr2, and Gr3), based on the adjunctive therapy usage were identified: Gr1 (n\u2009=\u200916) was without adjunctive therapy, two other groups (Gr2 and Gr3) were with adjunctive medicines, such as 2-ethyl-6-methyl-3-hydroxypyridine succinate (EMHS; Gr2,\n                      <jats:italic>n<\/jats:italic>\n                      =\u200920), or other drugs, such as citicoline, cerebrolysin, cortexin, actovegin, gliatilin (choline alfoscerate; Gr3,\n                      <jats:italic>n<\/jats:italic>\n                      =\u200923). The enzymatic activities were assessed also in the matched control group (\n                      <jats:italic>n<\/jats:italic>\n                      =\u200938). In all three patient groups, as compared with controls, activity of erythrocyte glutathione reductase was decreased at baseline and after the treatment course. In Gr2, unlike Gr1 or Gr3, there was a significant decrease in baseline glutamate dehydrogenase and glutathione-S-transferase activities. Certain clinical criteria were also elucidated for prescription of EMHS as adjunctive therapy for patients of Gr2. Glutamate dehydrogenase and glutathione-S-transferase activities returned closer to control levels after the treatment course in Gr2, unlike Gr1, where they declined yet more after psychotropic treatment without adjunctive medicine. Different significant links between biochemical parameters and scores by clinical scales were observed in Gr1, Gr2, and Gr3, some having predictive value for evaluation of antipsychotic treatment efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We demonstrate the validity of adjunctive neuroprotective medicines\u2019 usage in addition to antipsychotic and antidepressant therapy in distinct subgroups of patients suffering with LOP, especially those who have prominent side effects accompanying their psychotropic treatment. Returning of biochemical parameters to control range following the treatment course observed in patients of the subgroup treated with adjunctive EMHS is evidence for their metabolism normalization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1319891","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T23:56:33Z","timestamp":1703116593000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Late onset psychosis treatment with adjunctive medicines"],"prefix":"10.3389","volume":"14","author":[{"given":"Irina","family":"Boksha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Savushkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Sheshenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tereshkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Prokhorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriya","family":"Pochueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnur","family":"Burbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2045125319882798","DOI":"10.1177\/2045125319882798","article-title":"Psychotic disorders in late life: a narrative review","volume":"9","author":"Tampi","year":"2019","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/09540261.2019.1670624","article-title":"Late-onset psychosis and very-late-onset-schizophrenia-like-psychosis: an updated systematic review","volume":"31","author":"Suen","year":"2019","journal-title":"Int Rev Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1176\/appi.ajp.157.2.172","article-title":"Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The international late-onset schizophrenia group","volume":"157","author":"Howard","year":"2000","journal-title":"Am J Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/07317115.2011.642943","article-title":"Late-onset schizophrenia: a review for clinicians","volume":"35","author":"Pearman","year":"2012","journal-title":"Clin Gerontol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1025414","DOI":"10.3389\/fpsyt.2022.1025414","article-title":"Crossroad between current knowledge and new perspective of diagnostic and therapy of late-onset schizophrenia and very late-onset schizophrenia-like psychosis: an update","volume":"13","author":"St\u0229pie\u0144-Wyrobiec","year":"2022","journal-title":"Front Psych"},{"key":"ref6","first-page":"199","article-title":"Antioxidant usage for correction of psychopharmacology motor side-effects","volume":"117","author":"Andrusenko","year":"1994","journal-title":"Biull Eksp Biol Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17116\/jnevro202012001162","article-title":"Vliianie Meksidola na tserebral'ny\u012d mitokhondriogenez v molodom vozraste i pri starenii [the effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging]","volume":"120","author":"Kirova","year":"2020","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref8","first-page":"35","article-title":"Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro","volume":"112","author":"Shchul\u2019kin","year":"2012","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.17116\/terarkh20168811121-127","article-title":"Use of succinate-containing agents in the treatment of infectious diseases","volume":"88","author":"Tikhonova","year":"2016","journal-title":"Ter Arkh"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.20953\/1729-9225-2020-2-97-102","article-title":"Antioxidants\/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19","volume":"18","author":"Voronina","year":"","journal-title":"Infect Dis"},{"key":"ref11","first-page":"28","article-title":"Mexidol as additional therapy for the patient with continuous paranoid type of schizophrenia in the presence of a late dyskinesia. P.B","volume":"4","author":"Dyakonov","year":"2011","journal-title":"Gannushkin Psychiatry Psychopharmacother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.17116\/jnevro2020120051160","article-title":"Possibilities of using Mexidol in the complex therapy of mental disorders","volume":"120","author":"Shamrey","year":"2020","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.17116\/jnevro202012004181","article-title":"Geroprotektivnye effekty etilmetilgidroksipiridina suktsinata v eksperimental'nom issledovanii [Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental study]","volume":"120","author":"Voronina","year":"","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.47877\/1560-957x-2021-10504","article-title":"Revealing subgroups of patients with late-onset depression basing on measurements of blood energy-, glutamate- and glutathione metabolism enzymatic activities","volume":"5","author":"Savushkina","year":"","journal-title":"Russian J Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.23934\/2223-9022-2018-7-1-44-52","article-title":"Metabolic therapy in patients with ischemic stroke","volume":"7","author":"Zavaliy","year":"2018","journal-title":"Russian Sklifosovsky J \u201cEmerg Med Care\u201d"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.17116\/jnevro202012008183","article-title":"Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment, cerebral circulation and morphological changes in the hippocampus of rats with chronic brain ischemia","volume":"120","author":"Tyurenkov","year":"2020","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.3390\/nu12103113","article-title":"Application of Citicoline in neurological disorders: a systematic review","volume":"12","author":"Jasielski","year":"2020","journal-title":"Nutrients"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/0004867411433213","article-title":"Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms","volume":"46","author":"Xiao","year":"2012","journal-title":"Aust N Z J Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.17116\/jnevro2021121031127","article-title":"Cortexin administration due to improvement of cognitive and behavioral disorders in children and teenagers with epilepsy","volume":"121","author":"Kalmykova","year":"2021","journal-title":"Zh Nevrol Psikhiatr Im SS Korsakova"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e0270497","DOI":"10.1371\/journal.pone.0270497","article-title":"Actovegin in the management of patients after ischemic stroke: a systematic review","volume":"17","author":"la Fleur","year":"2022","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1161\/STROKEAHA.116.014321","article-title":"ARTEMIDA trial (a randomized trial of efficacy, 12 months international double-blind Actovegin): a randomized controlled trial to assess the efficacy of Actovegin in Poststroke cognitive impairment","volume":"48","author":"Guekht","year":"2017","journal-title":"Stroke"},{"key":"ref22","first-page":"69","article-title":"Efficacy of actovegin in the treatment of elderly patients with vascular mild cognitive impairment","volume":"113","author":"Mikha\u012dlova","year":"2013","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17116\/jnevro202012002131","article-title":"Kholinergicheski\u012d profil' kak mishen' ratsional'no\u012d terapii zabolevani\u012d i travm tsentral'no\u012d nervno\u012d sistemy [cholinergic profile as a target of rational therapy of central nervous system diseases and injuries]","volume":"120","author":"Litvinenko","year":"2020","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1148166","DOI":"10.3389\/fendo.2023.1148166","article-title":"Choline supplements: An update","volume":"14","author":"Kansakar","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"ref26","first-page":"218","volume-title":"Clinical global impressions, ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3390\/nu14163367","article-title":"Nootropics as cognitive enhancers: types, dosage and side effects of smart drugs","volume":"14","author":"Mal\u00edk","year":"2022","journal-title":"Nutrients"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.17816\/nb87427","article-title":"The use of antioxidant medicine as an adjunctive therapy in late-onset schizophrenia spectrum disorders","author":"Savushkina","year":"","journal-title":"Neurol Bull"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.17116\/jnevro201911902161","article-title":"Glutathione reductase and glutathione-S-transferase in blood cells in schizophrenia and schizophrenia spectrum disorders","volume":"119","author":"Tereshkina","year":"2019","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00406-022-01396-7","article-title":"Links of platelet glutamate and glutathione metabolism with attenuated positive and negative symptoms in depressed patients at clinical high risk for psychosis","volume":"273","author":"Boksha","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2478\/jomb-2019-0018","article-title":"Platelet glutamate dehydrogenase activity and efficacy of antipsychotic therapy in patients with schizophrenia","volume":"39","author":"Savushkina","year":"2020","journal-title":"J Med Biochem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/acps.12873","article-title":"The relationship between negative symptoms and depression in schizophrenia: a systematic review","volume":"137","author":"Krynicki","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/schbul\/sbw097","article-title":"Depression and schizophrenia: cause, consequence, or trans-diagnostic issue?","volume":"43","author":"Upthegrove","year":"2017","journal-title":"Schizophr Bull"},{"key":"ref37","first-page":"90","article-title":"Depression in schizophrenia: diagnosis and treatment","volume":"113","author":"Mazo","year":"2013","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00406-008-2011-4","article-title":"Evidence for separate diseases: stages of one disease or different combinations of symptom dimensions?","volume":"2","author":"Hafner","year":"2008","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.31083\/j.fbs1401004","article-title":"Integrated pathophysiology of schizophrenia, major depression, and bipolar disorder as monoamine axon disorder","volume":"14","author":"Nakamura","year":"2022","journal-title":"Front Biosci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0920-9964(94)90017-5","article-title":"Specificity of the Calgary depression scale. A structured interview guide for the Hamilton depression rating scale","volume":"11","author":"Addington","year":"1994","journal-title":"Schizophr Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.31550\/1727-2378-2021-20-5-55-61","article-title":"Use of parametric methods and questionnaires for the study of depressive and anxiety disorders in schizophrenia","volume":"20","author":"Novitskiy","year":"2021","journal-title":"Doctor Ru"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"CD004162","DOI":"10.1002\/14651858.CD004162.pub2","article-title":"Antipsychotic drug treatment for elderly people with late-onset schizophrenia","volume":"2","author":"Essali","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.14412\/2074-2711-2014-2-4-12","article-title":"Therapeutic collaboration (compliance): content of the definition, mechanisms of formation, and methods of optimization","volume":"6","author":"Danilov","year":"2014","journal-title":"Neurol Neuropsychiatry Psychosomat"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1319891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T23:56:37Z","timestamp":1703116597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1319891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":45,"alternative-id":["10.3389\/fpsyt.2023.1319891"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1319891","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"article-number":"1319891"}}